

associated with speech and language, Broca's area and Wernicke's area, might explicate the etiology of stuttering (1).

Briefly, Perkins says these areas function at cognitive rates too slow to be considered a source of stuttering. Perkins cites George Miller's studies, decades ago, indicating that the human cognitive rate is

7 ± 2 thoughts per second, the same as the rate of syllable production, which is under voluntary control (2). Perkins maintains, "Any cause of stuttering has to account for why it can be involuntary and ... how high-speed speech sounds can be produced with low-speed cognitive and linguistic equipment."

Certainly, Broca's area and Wernicke's area can process data more rapidly than 7 ± 2 items per second. Miller's review related to issues of absolute judgement and immediate memory when humans are in a stimulus-response setting or functioning in a communication system. He discussed how brains overcome the apparent 7 ± 2 limit, for instance, by making stimuli multidimensional, and he emphasized that such recoding power-

fully increases the amount of information that can be processed. Our language, he commented, can repackaged material into a few chunks rich in information (2).

Without demonstration of an equivalency between how we process the stimulus input we memorize and how we process spontaneous thought for speech/language production, the 7 ± 2 limit lacks merit when applied to linguistic encoding of thoughts. Regardless, there is no neuroscientific data indicating that we think at the rate at which we talk, not to mention that there is no denotation of what a "thought" is.

Foundas' discovery that abnormalities in the anatomic substrate of language might differ among stutterers raises the possibility that some have difficulty processing speech-motor control because of aberrancies in the frontal opercular areas (Broca's), others because of aberrancies near Wernicke's area. Their research has far-reaching implications: Perhaps stutters with anterior versus posterior gyral abnormalities differ in severity of their disorder, genetic background, or response to speech or pharmacologic therapy.

DAVID B. ROSENFELD,*

NAGALAPURA S. VISWANATH

Stuttering Center, Speech Motor Control Laboratory, Department of Neurology, Baylor College of

Medicine, Houston, TX 77030, USA

*To whom correspondence should be addressed.

E-mail: davidr@bcm.tmc.edu

References and Notes


1. A. L. Foundas et al., *Neurology* **57**, 207 (2001).
2. G. Miller, *The Psychology of Communication* (Basic Books, New York, 1967).

CORRECTIONS AND CLARIFICATIONS

REPORTS: "Direct determination of the timing of sea level change during Termination II" by C. D. Gallup, H. Cheng, F. W. Taylor, R. L. Edwards (11 Jan., p. 310). On page 312, in the second column, the initial sea level value was erroneously given as 8 ± 5 m below present sea level. The correct value is 38 ± 5 m below present sea level. And in the legend for Fig. 2C, the SPECMAC record is not benthic but planktonic.

BOOKS ET AL.: "The pill in context" by L. Schiebinger (7 Dec., p. 2106). The caption that accompanied this review of Lara V. Marks' book *Sexual Chemistry: A History of the Contraceptive Pill* was mislabeled. The 1979 poster showing women how to use the pill was identified as Malaysian, but is Thai.

CREDIT: PRESTON MORRIS/IAN



GCI Introduces Commercial DNA and Tissue Banking

GCI offers biorepository services for collecting, processing and storage of **DNA**, **SERA**, and **TISSUE SPECIMENS** to support industry, academic and governmental scientific research programs.

GCI offers contract services in collecting, storing, and processing biological specimens as well as clinical data management of case record information. In addition, GCI's Global Physician Network™ of physicians and Global Repository™ of disease samples and controls is available to support your research programs.

GCI services include:

- Processing and storing biological materials, including DNA, tissue, and sera
- Access to existing inventory of DNA, tissue, sera disease cases and controls
- Lymphocyte storage cell-line extension
- Prospective sample collections
- Clinical data management
- High throughput genotyping

GCI has collected and processed specimens from over 100,000 patients and utilizes state of the art specimen tracking software to provide secure and discrete patient confidentiality.

Let GCI help you reduce costs and time to market.

Call today for more information on how we can support your exclusive research: Ask for the Business Development Office at **1.877.GENOMIX** Or visit our web site: **WWW.GENOMICSINC.COM**

